Inotuzumab ozogamicine

Inotuzumab ozogamicin (CMC-544) is an anti-CD22 antibody-drug conjugate (ADC). Inotuzumab ozogamicin consists of a humanized IgG4 anti-CD22 mAb, covalently linked to Calicheamicin via an acid-labile AcBut (HY-132261) linker. The antibody portion is Inotuzumab (HY-P99264), and the drug-linker conjugate for ADC is N-Ac-γ-Calicheamicin-AcBut-NHS ester (HY-103688). Inotuzumab ozogamicin binds to the minor groove of DNA, inducing double-strand cleavage and subsequent apoptosis. Inotuzumab ozogamicin can be used for the study of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

635715-01-4

CMC-544; PF-5208773; WAY-207294

12352203

Antibody-Drug Conjugates (ADCs) ; Apoptosis; CD22; DNA/RNA Synthesis

Antibody-drug Conjugate/ADC Related; Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation

Cancer-programmed cell death

Cancer

H2O

[Inotuzumabozogamicin]

[1]Bruzzese A, et al. Therapeutic Strategies for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies. Eur J Haematol. 2025 Jun;114 (6) :938-952.

Dry Ice

http://file.medchemexpress.com/batch_PDF/HY-P9959/

Inhibitory Antibodies

Launched